The human arsenal is loaded with all sorts of valuable elements, but one that sticks out the most is our ability to work around things. This ability has helped us big time in regards to moving forward on a rather consistent basis. Now, when you are functioning within such a progressive dynamic, you end up bringing yourself closer to a lot of notable by-products. Nevertheless, if you talk about the real-world setting, we are still yet to see anything as notable as technology. Technology gets to be the clear winner here for a reason that is bigger than just its ingenious skill-set. It is actually rooted in the way the creation impacted our entire spectrum, including a highly-critical medical sector. Technology’s link-up with healthcare was a pivotal moment, as it arrived at a time when the sector was already falling apart on the back of all its obsolete ideas. Hence, it triggered a much needed transition, but even after that was done, the link-up would continue to produce new and improved prospects. In fact, one recent acquisition does a lot in terms of keeping up with that trend.
Pfizer has officially acquired Biohaven Pharmaceuticals in a deal worth around $11.6 billion. According to the agreed terms, Pfizer will fork out $148.50 for each Biohaven share it doesn’t already own. This number makes up for 78.6% premium to Biohaven’s closing stock price on Monday, and a 33% premium to the stock’s average price over the last three months. Interestingly enough, the deal gets Pfizer a promising oral migraine drug in Nurtec, a drug hailing from a new class of migraine medicines that target calcitonin gene-related peptide (CGRP), which is basically a protein whose levels rise with the onset of migraine attacks. Beyond that, the company will also get a nasal spray migraine drug candidate zavegepant, along with five preclinical assets that address the same pain target. As for other Biohaven assets, they’ll go on to make a whole new publically traded company led by Biohaven’s existing management.
“We believe Pfizer is uniquely positioned to help the portfolio reach its full potential given our leading scale and capabilities, including comprehensive field force engagement with primary care physicians, specialists and health systems delivering the right information at the right time,” Nick Lagunowich, president of Pfizer Internal Medicine.
Going back to Nurtec for a second, it is an important pick up from Pfizer’s standpoint, and we say so largely because of its financial potential. In 2021, the drug generated over $462.5 million in sales, achieving a 600% increase, if compared to the 2020 sales. This year, Nurtec has already secured $123.6 million in the first quarter. Nevertheless, Pfizer won’t be the only beneficiary of all the further sales. The new Biohaven’s spinout is also positioned to receive tiered royalties from Nurtec or zavegepant sales in the US.
